Product Code: GVR-4-68040-040-3
Genetic Testing Market Growth & Trends:
The global genetic testing market size is anticipated to reach USD 39.25 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 22.5% from 2025 to 2030. The growth of the genetic testing industry is majorly attributed to the rising prevalence of genetic conditions, increasing investments in R&D, and initiatives by prominent market players. Moreover, increasing emphasis on personalized medicines is also likely to have a positive impact on the direct-to-consumer genetic testing industry.
Furthermore, government authorities are focusing on implementing national programs to encourage and consolidate genetic research. The primary goal of these national genetic research programs is to increase their investments in the compilation of data with an aim to develop personalized treatment plans and medicines, suitable for diverse ethnicities equally. To achieve this goal, awareness and acceptance of genetic testing is expected to play a crucial role.
Genetic testing has major applications in the diagnosis and monitoring of chronic illnesses such as cancers. Owing to increasing incidences of various forms of cancers, and a relatively higher rate of remission provided by the use of testing methodologies, it is expected that this segment with grow at the fastest growth rate in the personalized diagnostics segment throughout the forecast period. In addition, companies are collaborating to integrate advanced informatics tools for efficient diagnosis of cancer which is further contributing to the segment growth.
For instance, in February 2021, Tempus entered in a collaboration with Precision Health Informatics for accelerating the advancement of Precision Medicine (PM) in oncology. Precision Health Informatics leveraged Tempus' genomic sequencing capabilities and AI-enabled platform to create an efficient personalized patient care and clinical research program.
Along with that, governments of various emerging countries are taking initiatives to establish an infrastructure for conducting testing. For instance, in 2021, Moh. Bin Rashid University of Medicine and Health Sciences and A.J. Children's Specialty Hospital (AJCH) collaborated to establish a new & unique scientific and medical interdisciplinary environment through the Al Jalila Genomics Center. Furthermore, the development of the Center for Genomic Discovery as part of the comprehensive academic health system will allow for advancements in genomics and gene discovery.
Genomic data can be used for a variety of purposes, including PM, diagnosis, and toxicogenomics. However, the analysis of massive amounts of data produced in studies is a significant challenge. In some instances, technical improvements have made it possible for the equipment to be used to give an assessment. Although, the process still relies heavily on the perception of the professional in-charge. Hence, the need for skilled professionals is likely to hamper the growth of the market in developing countries.
Genetic Testing Market Report Highlights:
- By technology, Next-generation sequencing is a relatively more mature segment and held the largest genetic testing industry share in 2024, Owing to the increasing number of pharmaceutical and biotechnology companies establishing in-house research stations for developing a personalized treatment for cancers
- By application, the genetic ancestry screening segment captured the majority of the market share in 2024, owing to the increasing genetic disorders in emerging markets
- By product,consumables are expected to capture the largest share of the market in 2024, owing to the increasing investment by governments and international bodies to adopt a technologically advanced workflow of clinical diagnostics
- By channel,online is expected to witness the fastest growth during the forecast period, owing to the increasing use of smartphone applications, such as ShareDNA, that offer relevant information about test results and interpretation
- By end-user, diagnostic laboratories are anticipated to be the fastest-growing segment. This growth can be attributed to the increasing collaborations and strategic partnerships between corporations and laboratories to develop personalized therapeutic formations
- North America has a dominant regional position in the genetic testing industry with 45.38% share of the overall market. The increasing incidence of diseases, such as chronic and infectious diseases, is encouraging companies to enter the regional ELISA analyzers market
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. Product
- 1.2.4. Channel
- 1.2.5. End Use
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. Product outlook
- 2.2.4. Channel outlook
- 2.2.5. End Use outlook
- 2.2.6. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Genetic Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Technological Advancements in Diagnostic Testing
- 3.2.1.2. Growing Burden of Chronic and Infection Diseases
- 3.2.1.3. Rising Awareness and Demand for Personalized Medicine
- 3.2.2. Market restraint analysis
- 3.2.2.1. Required Skilled Labors
- 3.3. Genetic Testing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Genetic Testing Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2024 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Genetic Testing Market by Technology Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Next-Generation Sequencing
- 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
- 4.4.2. Array Technology
- 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.3. PCR - Based Testing
- 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.4. FISH
- 4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.5. Others
- 4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Genetic Testing Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2024 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Genetic Testing Market by Application Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Ancestry & Ethnicity
- 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
- 5.4.2. Traits Screening
- 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.3. Genetic Disease Carrier Status
- 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.4. New Baby Screening
- 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.5. Health and Wellness - Predisposition/ Risk/tendency
- 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Genetic Testing Market: Product Estimates & Trend Analysis
- 6.1. Product Market Share, 2024 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Genetic Testing Market by Product Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Consumables
- 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
- 6.4.2. Equipment
- 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.3. Software & Services
- 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Genetic Testing Market: Channel Estimates & Trend Analysis
- 7.1. Channel Market Share, 2024 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Genetic Testing Market by Channel Outlook
- 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Online
- 7.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
- 7.4.2. Offline
- 7.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Genetic Testing Market: End Use Estimates & Trend Analysis
- 8.1. End Use Market Share, 2024 & 2030
- 8.2. Segment Dashboard
- 8.3. Global Genetic Testing Market by End Use Outlook
- 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.4.1. Hospitals & Clinics
- 8.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
- 8.4.2. Diagnostic Laboratories
- 8.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
- 8.4.3. Others
- 8.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Genetic Testing Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2024 & 2030
- 9.2. Regional Market Dashboard
- 9.3. Global Regional Market Snapshot
- 9.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
- 9.5. North America
- 9.5.1. U.S.
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.2. Canada
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.3. Mexico
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million
- 9.6. Europe
- 9.6.1. UK
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.2. Germany
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.3. France
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework/ reimbursement structure
- 9.6.3.3. Competitive scenario
- 9.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.4. Italy
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework/ reimbursement structure
- 9.6.4.3. Competitive scenario
- 9.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.5. Spain
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework/ reimbursement structure
- 9.6.5.3. Competitive scenario
- 9.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.6. Norway
- 9.6.6.1. Key country dynamics
- 9.6.6.2. Regulatory framework/ reimbursement structure
- 9.6.6.3. Competitive scenario
- 9.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.7. Sweden
- 9.6.7.1. Key country dynamics
- 9.6.7.2. Regulatory framework/ reimbursement structure
- 9.6.7.3. Competitive scenario
- 9.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.8. Denmark
- 9.6.8.1. Key country dynamics
- 9.6.8.2. Regulatory framework/ reimbursement structure
- 9.6.8.3. Competitive scenario
- 9.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7. Asia Pacific
- 9.7.1. Japan
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.2. China
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.3. India
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.4. Australia
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.5. South Korea
- 9.7.5.1. Key country dynamics
- 9.7.5.2. Regulatory framework/ reimbursement structure
- 9.7.5.3. Competitive scenario
- 9.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.6. Thailand
- 9.7.6.1. Key country dynamics
- 9.7.6.2. Regulatory framework/ reimbursement structure
- 9.7.6.3. Competitive scenario
- 9.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.8. Latin America
- 9.8.1. Brazil
- 9.8.1.1. Key country dynamics
- 9.8.1.2. Regulatory framework/ reimbursement structure
- 9.8.1.3. Competitive scenario
- 9.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.8.2. Argentina
- 9.8.2.1. Key country dynamics
- 9.8.2.2. Regulatory framework/ reimbursement structure
- 9.8.2.3. Competitive scenario
- 9.8.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.9. MEA
- 9.9.1. South Africa
- 9.9.1.1. Key country dynamics
- 9.9.1.2. Regulatory framework/ reimbursement structure
- 9.9.1.3. Competitive scenario
- 9.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.9.2. Saudi Arabia
- 9.9.2.1. Key country dynamics
- 9.9.2.2. Regulatory framework/ reimbursement structure
- 9.9.2.3. Competitive scenario
- 9.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.9.3. UAE
- 9.9.3.1. Key country dynamics
- 9.9.3.2. Regulatory framework/ reimbursement structure
- 9.9.3.3. Competitive scenario
- 9.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.9.4. Kuwait
- 9.9.4.1. Key country dynamics
- 9.9.4.2. Regulatory framework/ reimbursement structure
- 9.9.4.3. Competitive scenario
- 9.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2024
- 10.3.4. 24 genetics
- 10.3.4.1. Company overview
- 10.3.4.2. Financial performance
- 10.3.4.3. Product benchmarking
- 10.3.4.4. Strategic initiatives
- 10.3.5. Circle DNA
- 10.3.5.1. Company overview
- 10.3.5.2. Financial performance
- 10.3.5.3. Product benchmarking
- 10.3.5.4. Strategic initiatives
- 10.3.6. TellmeGen
- 10.3.6.1. Company overview
- 10.3.6.2. Financial performance
- 10.3.6.3. Product benchmarking
- 10.3.6.4. Strategic initiatives
- 10.3.7. 23andme
- 10.3.7.1. Company overview
- 10.3.7.2. Financial performance
- 10.3.7.3. Product benchmarking
- 10.3.7.4. Strategic initiatives
- 10.3.8. AncestryDNA
- 10.3.8.1. Company overview
- 10.3.8.2. Financial performance
- 10.3.8.3. Product benchmarking
- 10.3.8.4. Strategic initiatives
- 10.3.9. MyDNA
- 10.3.9.1. Company overview
- 10.3.9.2. Financial performance
- 10.3.9.3. Product benchmarking
- 10.3.9.4. Strategic initiatives
- 10.3.10. Igenomix
- 10.3.10.1. Company overview
- 10.3.10.2. Financial performance
- 10.3.10.3. Product benchmarking
- 10.3.10.4. Strategic initiatives
- 10.3.11. Myriad Genetics, Inc
- 10.3.11.1. Company overview
- 10.3.11.2. Financial performance
- 10.3.11.3. Product benchmarking
- 10.3.11.4. Strategic initiatives
- 10.3.12. Illumina, Inc.
- 10.3.12.1. Company overview
- 10.3.12.2. Financial performance
- 10.3.12.3. Product benchmarking
- 10.3.12.4. Strategic initiatives
- 10.3.13. MyHeritage Ltd.
- 10.3.13.1. Company overview
- 10.3.13.2. Financial performance
- 10.3.13.3. Product benchmarking
- 10.3.13.4. Strategic initiatives